SNM Unveils Bridge for Imaging Biomarker Use in Clinical Trials

---

The Society of Nuclear Medicine (SNM) has created the Molecular Imaging Clinical Trials Network in response to the need for streamlined processes for using imaging biomarkers in clinical research and practice.

There is widespread agreement that the use of imaging biomarkers in the drug development process can reduce the complexity and cost of the regulatory process and speed the timelines to clinical use. SNM has designed a model for the use of imaging biomarkers in clinical trials that spans drug development, molecular imaging, radiolabeled probe development and manufacturing and regulatory issues to integrate the use of investigational imaging biomarkers into multicenter clinical trials, according to SNM President Robert W. Atcher, PhD.

Read More

CLOSE